THOMSON REUTERS
CORTELLIS™

# MacroGenics Inc

## COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 06-Aug-2014

**THOMSON REUTERS**
3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

Return to Table of Contents



THOMSON REUTERS

# ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurateand validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

Return to Table of Contents

# GLOSSARY

**Number of Drugs in Active Development**

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

**Number of Inactive Drugs**

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

**Number of Patents as Owner**

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

**Number of Patents as Third Party**

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

**Patents summary table**

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

**Number of Deals**

A count of deals where the company or one of its subsidiaries is the primary company.

**Key Indications**

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

**Key Target-based Actions**

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

**Key Technologies**

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Return to Table of Contents

**PLEASE NOTE:** the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

Return to Table of Contents

## TABLE OF CONTENTS



Return to Table of Contents

# MacroGenics Inc

## COMPANY OVERVIEW

| | |
|---|---|
| **Company Name** | MacroGenics Inc |
| **Parent Company Name** | MacroGenics Inc |
| **Website** | http://www.macrogenics.com/ |
| **Country** | US |
| **Number of Drugs in Active Development** | 13 |
| **Number of Inactive Drugs** | 14 |
| **Number of Patents as Owner** | 56 |
| **Number of Patents as Third Party** | 1 |
| **Number of Deals** | 34 |
| **Key Indications** | Cancer,Autoimmune disease,Solid tumor,Insulin dependent diabetes,Breast tumor,Inflammatory disease,Rheumatoid arthritis,Systemic lupus erythematosus,Acute myelogenous leukemia,Chikungunya virus infection,Dengue virus infection,Esophagus tumor,Influenza virus infection,Transplant rejection,Variola virus infection |
| **Key Target-based Actions** | Immunoglobulin gamma Fc receptor III antagonist,CD276 antigen inhibitor,Erbb2 tyrosine kinase receptor inhibitor,Immunoglobulin gamma Fc receptor II antagonist,Immunoglobulin gamma Fc receptor II modulator,B-lymphocyte antigen CD20 inhibitor,Insulin-like growth factor 1 antagonist,ADAM-9 modulator,B-lymphocyte antigen CD19 modulator,CD79b agonist,CD79b modulator,CDw123 modulator,Carboxypeptidase inhibitor,Cell surface A33 antigen modulator,Epidermal growth factor antagonist,Immunoglobulin gamma Fc receptor II agonist,Oncostatin M |
| **Key Technologies** | Biological therapeutic,Parenteral formulation unspecified,Monoclonal antibody humanized,Antibody,Multivalent antibody,Monoclonal antibody,Intravenous formulation,Injectable formulation,Humanized antibody,Chimeric antibody,Drug combination,Immunoglobulin-G |

## COMPANY PROFILE

### SUMMARY

MacroGenics Inc, incorporated in August 2000 and based in Rockville, Maryland, is focused on the development of novel immunotherapeutics. Product candidates include monoclonal antibodies and vaccines for the treatment and prevention of cancer, autoimmune and infectious disease. Programs are derived from both in-house discoveries and in-licensed candidates.

### COMPANY LOCATION

MacroGenics is headquartered in Rockville, Maryland. The company has developed platform technology at three sites. These include protein engineering and animal modeling in Rockville, proteomics and target discovery in Seattle, Washington and genetic immunization and vaccine development in Dallas, Texas. In October 2005, MacroGenics opened a cGMP manufacturing facility in Rockville, MD. In February 2014, MacroGenics planned to expand its manufacturing facility, to increase its production capacity, using approximately US $5 to 10 million.

### ACQUISITIONS AND SPIN-OFFS

In July 2008, MacroGenics acquired Raven Biotechnologies. The company would issue shares of its common stock in the transaction but further financial details were not disclosed.

In June 2002, MacroGenics acquired Eliance Biotechnology Inc, a private vaccine discovery company located in Dallas,TX, which was founded to exploit technology developed at The University of Texas Southwestern Medical Center at Dallas Center for Biomedical Inventions. The company and university also formed an alliance to discover and develop immunotherapeutics to prevent and treat cancer, autoimmune and infectious diseases. In the same month, MacroGenics raised $12.6 million in financing.

Return to Table of Contents

## LICENSING AGREEMENTS

In October 2004, MacroGenics acquired exclusive rights to develop compounds against a cancer target identified using OriGene Technologies Inc's Rapid-Scan technology. MacroGenics was to focus on the development of therapeutic monoclonal antibody candidates against this molecule. OriGene would receive option fees, milestones and royalty payments.

In April 2004, Neose Technologies Inc and MacroGenics entered into a monoclonal antibodies research collaboration and license agreement. Neose was to apply its GlycoAdvance and GlycoPEGylation technologies to improve the therapeutic properties of MacroGenics compounds. MacroGenics had the right to take remodeled compounds into development. Following the initial research phase, MacroGenics was to be responsible for funding the further development of these licensed compounds. In exchange, Neose was to be entitled to receive option fee, milestone, and royalty payments as products were developed and commercialized.

In May 2002, MacroGenics licensed a therapeutic target induced by Epstein-Barr virus from EBVax Inc and Tufts University. MacroGenics was to launch a research program to identify treatments to reduce morbidity in patients suffering from the acute and chronic consequences of EBV infection. For a worldwide, exclusive license to the technology, MacroGenics agreed to certain upfront fees, milestone and royalty payments contingent on achieving specific preclinical and clinical objectives in different clinical indications.

In September 2001, MacroGenics reported the completion of several key license agreements relating to its core intellectual property.

## EARLY R&D

**IN OCTOBER 2010, BOEHRINGER INGELHEIM AND MACROGENICS ENTERED A GLOBAL ALLIANCE TO DISCOVER, DEVELOP AND COMMERCIALIZE ANTIBODY THERAPEUTICS, BASED ON MACROGENICS' DUAL-AFFINITY RE-TARGETING (DART) PLATFORM, WHICH WOULD BE DIRECTED AGAINST UP TO TEN COMBINATIONS OF MOLECULAR TARGETS. THERAPEUTIC AREAS FOR THE DRUG CANDIDATES COULD INCLUDE IMMUNOLOGY, ONCOLOGY, RESPIRATORY, CARDIOMETABOLIC AND INFECTIOUS DISEASES. THE COMPANIES WOULD SHARE DISCOVERY AND CERTAIN PRECLINICAL ACTIVITY RESPONSIBILITY. AFTERWHICH, BOEHRINGER INGELHEIM WOULD BE SOLELY RESPONSIBLE FOR FURTHER PRECLINICAL, CLINICAL, REGULATORY, COMMERCIAL AND MANUFACTURING ACTIVITIES OF ANY RESULTING PRODUCTS. MACROGENICS WAS EXPECTED TO RECEIVE $60 MILLION, COMPRISED OF AN UPFRONT CASH PAYMENT, ANNUAL MAINTENANCE FEES, R&D FUNDING, AND NEAR-TERM RESEARCH-BASED MILESTONES, DURING THE FIRST THREE YEARS OF THE ALLIANCE. BOEHRINGER INGELHEIM ALSO EXPECTED TO MAKE A FUTURE EQUITY INVESTMENT IN MACROGENICS. FURTHERMORE, MACROGENICS COULD RECEIVE DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS OF UP TO $210 MILLION FOR EACH OF THE TEN DART PROGRAMS, PLUS TIERED ROYALTIES. MACROGENICS WOULD HAVE AN OPTION TO COPROMOTE CERTAIN DART PRODUCTS IN THE US.**

## FINANCIAL

In February 2014, MacroGenics commenced an underwritten public offering of 2.5 million shares of its common stock, consisting of 1.5 million shares to be offered by MacroGenics and 1 million shares to be offered by existing stockholders. The underwriters were to be granted a 30-day option to purchase up to 375,000 shares of common stock; later that month, the company priced the offering of 3 million shares of its common stock, consisting of 1.8 million shares to be offered by MacroGenics and 1.2 million shares to be offered by existing stockholders at a price of $36.50 per share. The underwriters were granted a 30-day option to purchase up to 450,000 shares of common stock. The offering was expected to close on February 18, 2014. Later in February 2014, the offering was completed for net proceeds of $76.7 million, including $15.4 million of net proceeds from full exercise of underwriters' over-allotment option.

In October 2013, MacroGenics offered an initial public offering of 5 million shares of its common stock, priced at $16 per share. Underwriters were granted a 30-day option to purchase up to an additional 750,000 shares of common stock to cover any over-allotments. The shares were to be traded on the NASDAQ Global Select Market under the ticker symbol "MGNX". The offering was expected to close on October 16, 2013. Later that month, shares of MacroGenics began trading on the NASDAQ Global Select Market. Later that month, the offering was closed and the company raised $83.8 million from the offering. The company offered 5,750,000 million shares of its common stock, at a price of $16 per share. Underwriters were granted a 30-day option to purchase up to an additional 750,000 shares of common stock to cover any over-allotments.

In September 2008, MacroGenics raised $25 million from a series D-2 financing round.

In May 2006, MacroGenics raised $45 million from a series C financing round. The proceeds were to be used to fund development of the company's anti-CD3 antibody; in phase II trials for type 1 diabetes and to advance drug programs in autoimmune diseases and cancer.

Return to Table of Contents

## SUBSIDIARY COMPANIES

| Names |
| --- |
| Raven Biotechnologies Inc |

## PRODUCT PORTFOLIO SUMMARY

## DRUGS

### Drugs by Indication

Active Drugs by Indication Chart




Return to Table of Contents

Drugs by Indication Table

| Indication | Active | Inactive | Total |
|---|---|---|---|
| Neoplasm | 6 | 10 | 16 |
| Immune disorder | 3 | 4 | 7 |
| Infectious disease | 4 | 2 | 6 |
| Gastrointestinal disease | 2 | 3 | 5 |
| Respiratory disease | 1 | 3 | 4 |
| Inflammatory disease | 2 | 1 | 3 |
| Genitourinary disease | 0 | 3 | 3 |
| Endocrine disease | 2 | 1 | 3 |
| Hematological disease | 1 | 2 | 3 |
| Neurological disease | 0 | 2 | 2 |
| Dermatological disease | 1 | 1 | 2 |
| Metabolic disorder | 2 | 0 | 2 |
| Musculoskeletal disease | 1 | 1 | 2 |
| Gynecology and obstetrics | 1 | 1 | 2 |
| Andrology | 0 | 1 | 1 |

Return to Table of Contents

## Drugs by Highest Status

Active Drugs by Highest Status Chart




Drugs by Highest Status Table

| Development Status | Number of Drugs |
|---|---|
| Phase 3 Clinical | 1 |
| Phase 2 Clinical | 1 |
| Phase 1 Clinical | 2 |
| Discovery | 9 |
| Discontinued | 3 |
| No Development Reported | 11 |

Return to Table of Contents

## DEALS

| Deal Type | Principal | | Partner | | Total |
|---|---|---|---|---|---|
| | Active | Inactive | Active | Inactive | |
| Technology - Other Proprietary | 3 | 0 | 1 | 0 | 4 |
| Drug - Funding | 6 | 0 | 0 | 0 | 6 |
| Drug - Screening/Evaluation | 2 | 0 | 0 | 0 | 2 |
| Drug - Early Research/Development | 0 | 0 | 3 | 0 | 3 |
| Drug - Development/Commercialization License | 10 | 0 | 4 | 0 | 15 |
| Drug - Manufacturing/Supply | 0 | 0 | 2 | 0 | 2 |
| Drug - Development Services | 0 | 0 | 1 | 0 | 1 |
| Technology - Delivery/Formulation | 0 | 0 | 1 | 0 | 1 |

## CLINICAL TRIALS

Trials by Condition Studied

| Condition Studied | Ongoing | All |
|---|---|---|
| Endocrine disease | 1 | 10 |
| Gastrointestinal disease | 0 | 9 |
| Metabolic disorder | 0 | 7 |
| Neoplasm | 2 | 7 |
| Immune disorder | 0 | 3 |
| Infectious disease | 0 | 3 |
| Neurological disease | 0 | 3 |
| Inflammatory disease | 0 | 3 |
| Gynecology and obstetrics | 1 | 2 |
| Dermatological disease | 0 | 2 |
| Musculoskeletal disease | 0 | 2 |
| Hematological disease | 1 | 1 |
| Genitourinary disease | 0 | 1 |
| Respiratory disease | 0 | 1 |

Return to Table of Contents

Trials by Phase

| Phase | Ongoing | All |
|---|---|---|
| Phase 3 | 0 | 2 |
| Phase 2 | 1 | 6 |
| Phase 1 | 1 | 11 |
| Phase not specified | 0 | 1 |

**Phase Definitions**

**Phase 3 Clinical**
Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

**Phase 2 Clinical**
Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

**Phase 1 Clinical**
Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS *

| Indication | As Owner | As Third Party | Total |
|---|---|---|---|
| Cardiovascular disease | 2 | 0 | 2 |
| Endocrine disease | 19 | 1 | 20 |
| Gastrointestinal disease | 19 | 1 | 20 |
| Genitourinary disease | 12 | 1 | 13 |
| Hematological disease | 9 | 0 | 9 |
| Andrology | 8 | 0 | 8 |
| Immune disorder | 31 | 0 | 31 |
| Musculoskeletal disease | 13 | 0 | 13 |
| Neoplasm | 43 | 1 | 44 |
| Ocular disease | 3 | 0 | 3 |
| Metabolic disorder | 10 | 0 | 10 |
| Mouth disease | 1 | 0 | 1 |
| Neurological disease | 10 | 0 | 10 |
| Respiratory disease | 10 | 1 | 11 |
| Infectious disease | 18 | 0 | 18 |

Return to Table of Contents

| | | | |
|---|---|---|---|
| Injury | 1 | 0 | 1 |
| Toxicity and intoxication | 1 | 0 | 1 |
| Inflammatory disease | 23 | 0 | 23 |
| Otorhinolaryngological disease | 1 | 0 | 1 |
| Gynecology and obstetrics | 13 | 1 | 14 |
| Dermatological disease | 13 | 1 | 14 |
| Surgical procedure | 1 | 0 | 1 |

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Return to Table of Contents

## PRODUCT PORTFOLIO DRUGS

**PLEASE NOTE**: Highest status refers to highest development of that drug for one of the active companies

### teplizumab

| | |
|---|---|
| **Drug Name** | teplizumab |
| **Key Synonyms** | teplizumab |
| **Originator Company** | Tolera Therapeutics Inc |
| **Active Companies** | MacroGenics Inc |
| **Inactive Companies** | Tolera Therapeutics Inc, Eli Lilly & Co |
| **Highest Status** | Phase 3 Clinical |
| **Active Indications** | Transplant rejection, Insulin dependent diabetes |
| **Target-based Actions** | |
| **Other Actions** | Anti-inflammatory, Immunosuppressant, Hypoglycemic agent, CD3 antagonist |
| **Technologies** | Monoclonal antibody, Subcutaneous formulation, Intravenous formulation, Infusion, Biological therapeutic |
| **Last Change Date** | 04-Dec-2013 |

### margetuximab

| | |
|---|---|
| **Drug Name** | margetuximab |
| **Key Synonyms** | margetuximab |
| **Originator Company** | MacroGenics Inc |
| **Active Companies** | MacroGenics Inc, Green Cross Corp |
| **Inactive Companies** | |
| **Highest Status** | Phase 2 Clinical |
| **Active Indications** | Esophagus tumor, Solid tumor, Breast tumor |
| **Target-based Actions** | Erbb2 tyrosine kinase receptor inhibitor |
| **Other Actions** | Anticancer protein kinase inhibitor, Anticancer monoclonal antibody |
| **Technologies** | Monoclonal antibody, Intravenous formulation, Infusion, Biological therapeutic |
| **Last Change Date** | 19-Jun-2014 |

Return to Table of Contents

## MGA-271

| | |
|---|---|
| **Drug Name** | MGA-271 |
| **Key Synonyms** | |
| **Originator Company** | MacroGenics Inc |
| **Active Companies** | Servier, MacroGenics Inc |
| **Inactive Companies** | |
| **Highest Status** | Phase 1 Clinical |
| **Active Indications** | Solid tumor |
| **Target-based Actions** | CD276 antigen inhibitor |
| **Other Actions** | Immunostimulant, Anticancer monoclonal antibody |
| **Technologies** | Monoclonal antibody humanized, Immunoglobulin-G, Intravenous formulation, Biological therapeutic, Protein recombinant |
| **Last Change Date** | 08-May-2014 |

## MGD-006

| | |
|---|---|
| **Drug Name** | MGD-006 |
| **Key Synonyms** | |
| **Originator Company** | MacroGenics Inc |
| **Active Companies** | Servier, MacroGenics Inc |
| **Inactive Companies** | |
| **Highest Status** | Phase 1 Clinical |
| **Active Indications** | Acute myelogenous leukemia |
| **Target-based Actions** | CDw123 modulator |
| **Other Actions** | CD3 modulator, Anticancer protein kinase inhibitor |
| **Technologies** | Multivalent antibody, Humanized antibody, Injectable formulation, Biological therapeutic, Parenteral formulation unspecified |
| **Last Change Date** | 22-Jul-2014 |

Return to Table of Contents

## monoclonal antibody cocktail (DART, smallpox), MacroGenics

| | |
|---|---|
| **Drug Name** | monoclonal antibody cocktail (DART, smallpox), MacroGenics |
| **Key Synonyms** | |
| **Originator Company** | MacroGenics Inc |
| **Active Companies** | MacroGenics Inc |
| **Inactive Companies** | |
| **Highest Status** | Discovery |
| **Active Indications** | Variola virus infection |
| **Target-based Actions** | |
| **Other Actions** | Antiviral, Unspecified drug target |
| **Technologies** | Monoclonal antibody humanized, Drug combination, Biological therapeutic, Parenteral formulation unspecified |
| **Last Change Date** | 14-Feb-2013 |

## H5N1 influenza mAb therapy, MacroGenics

| | |
|---|---|
| **Drug Name** | H5N1 influenza mAb therapy, MacroGenics |
| **Key Synonyms** | |
| **Originator Company** | MacroGenics Inc |
| **Active Companies** | MacroGenics Inc |
| **Inactive Companies** | |
| **Highest Status** | Discovery |
| **Active Indications** | Influenza virus infection |
| **Target-based Actions** | |
| **Other Actions** | Unspecified drug target, Antiviral |
| **Technologies** | Monoclonal antibody humanized, Biological therapeutic, Parenteral formulation unspecified |
| **Last Change Date** | 15-Feb-2013 |

Return to Table of Contents

## CD32BxCD79B DART antibody (autoimmune disease), MacroGenics

| | |
|---|---|
| **Drug Name** | CD32BxCD79B DART antibody (autoimmune disease), MacroGenics |
| **Key Synonyms** | |
| **Originator Company** | MacroGenics Inc |
| **Active Companies** | MacroGenics Inc |
| **Inactive Companies** | |
| **Highest Status** | Discovery |
| **Active Indications** | Inflammatory disease, Autoimmune disease |
| **Target-based Actions** | Immunoglobulin gamma Fc receptor II agonist, CD79b agonist |
| **Other Actions** | Anti-inflammatory, Anticancer |
| **Technologies** | Antibody, Biological therapeutic |
| **Last Change Date** | 04-Dec-2013 |

## monoclonal antibody (DART, dengue virus infection), MacroGenics

| | |
|---|---|
| **Drug Name** | monoclonal antibody (DART, dengue virus infection), MacroGenics |
| **Key Synonyms** | |
| **Originator Company** | MacroGenics Inc |
| **Active Companies** | MacroGenics Inc |
| **Inactive Companies** | |
| **Highest Status** | Discovery |
| **Active Indications** | Dengue virus infection |
| **Target-based Actions** | |
| **Other Actions** | Antiviral, Unspecified drug target |
| **Technologies** | Immunoglobulin, Monoclonal antibody, Biological therapeutic, Parenteral formulation unspecified |
| **Last Change Date** | 15-Feb-2013 |

Return to Table of Contents

## bispecific antibodies (DART, cancer), MacroGenics/ Pfizer

| | |
|---|---|
| **Drug Name** | bispecific antibodies (DART, cancer), MacroGenics/ Pfizer |
| **Key Synonyms** | |
| **Originator Company** | MacroGenics Inc |
| **Active Companies** | Pfizer Inc, MacroGenics Inc |
| **Inactive Companies** | |
| **Highest Status** | Discovery |
| **Active Indications** | Cancer |
| **Target-based Actions** | B-lymphocyte antigen CD19 modulator, Epidermal growth factor antagonist, Insulin-like growth factor 1 antagonist |
| **Other Actions** | Anticancer protein kinase inhibitor, Anticancer antibody, CD3 agonist |
| **Technologies** | Multivalent antibody, Biological therapeutic |
| **Last Change Date** | 04-Dec-2013 |

## humanized mAbs (Chikungunya virus infection), MacroGenics/Washington University

| | |
|---|---|
| **Drug Name** | humanized mAbs (Chikungunya virus infection), MacroGenics/Washington University |
| **Key Synonyms** | |
| **Originator Company** | MacroGenics Inc |
| **Active Companies** | Washington University in St Louis, MacroGenics Inc |
| **Inactive Companies** | |
| **Highest Status** | Discovery |
| **Active Indications** | Chikungunya virus infection |
| **Target-based Actions** | |
| **Other Actions** | Antiviral, Unspecified drug target |
| **Technologies** | Monoclonal antibody humanized, Biological therapeutic, Parenteral formulation unspecified |
| **Last Change Date** | 14-Feb-2013 |

Return to Table of Contents

## MGD-007

| | |
|---|---|
| **Drug Name** | MGD-007 |
| **Key Synonyms** | |
| **Originator Company** | MacroGenics Inc |
| **Active Companies** | MacroGenics Inc, Servier |
| **Inactive Companies** | |
| **Highest Status** | Discovery |
| **Active Indications** | Cancer |
| **Target-based Actions** | Cell surface A33 antigen modulator |
| **Other Actions** | CD3 modulator, Anticancer antibody |
| **Technologies** | Multivalent antibody, Injectable formulation, Biological therapeutic, Parenteral formulation unspecified |
| **Last Change Date** | 25-Jul-2014 |

## MGD-010

| | |
|---|---|
| **Drug Name** | MGD-010 |
| **Key Synonyms** | |
| **Originator Company** | MacroGenics Inc |
| **Active Companies** | MacroGenics Inc |
| **Inactive Companies** | |
| **Highest Status** | Discovery |
| **Active Indications** | Autoimmune disease, Systemic lupus erythematosus, Rheumatoid arthritis |
| **Target-based Actions** | Immunoglobulin gamma Fc receptor II modulator, CD79b modulator |
| **Other Actions** | Immunomodulator, Anti-inflammatory |
| **Technologies** | Multivalent antibody, Injectable formulation, Biological therapeutic, Parenteral formulation unspecified |
| **Last Change Date** | 19-Jun-2014 |

Return to Table of Contents

## anti-CD3/undisclosed antibodies (DART/injectable, cancer), Macrogenics/Servier

| | |
|---|---|
| **Drug Name** | anti-CD3/undisclosed antibodies (DART/injectable, cancer), Macrogenics/Servier |
| **Key Synonyms** | |
| **Originator Company** | MacroGenics Inc |
| **Active Companies** | MacroGenics Inc, Servier |
| **Inactive Companies** | |
| **Highest Status** | Discovery |
| **Active Indications** | Cancer |
| **Target-based Actions** | |
| **Other Actions** | CD3 antagonist, Anticancer antibody |
| **Technologies** | Multivalent antibody, Injectable formulation, Biological therapeutic, Parenteral formulation unspecified |
| **Last Change Date** | 04-Dec-2013 |

Return to Table of Contents

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:
http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.



Return to Table of Contents